Skip to main content


Figure 2 | Breast Cancer Research

Figure 2

From: Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study

Figure 2

Overall survival since time of diagnosis by HR status and receipt adjuvant trastuzumab. Note: Reference group are those who are HR positive and received Trastuzumab. HR, Hormone receptor; TRZ, Trastuzumab. Adjusted by age, race/ethnicity, stage at diagnosis, grade and year of diagnosis.

Back to article page